Bayer and Almirall co-promocionarán the anticoagulant Rivaroxaban in Spain.
-Rivaroxaban, an oral anticoagulant innovative developed by Bayer, is a new option for the prevention of stroke in patients with atrial fibrillation recently approved in Europe and USA
-atrial fibrillation (AF) is the most common cardiac arrhythmia, and affects more than 6 million people in Europe. People with atrial fibrillation are five times more likely to suffer a stroke than the rest of the population
-the co-promotion of the anticoagulant begins in the coming months
Barcelona, February 2012.- Bayer and Almirall announced an agreement for co – promote Rivaroxaban (Xarelto ®) in Spain, which will begin in the coming months. Rivaroxaban, an oral anticoagulant developed by Bayer, is the only new oral anticoagulant approved for three indications in Europe.
Atrial fibrillation is the most common cardiac arrhythmia, and affects more than 6 million people in Europe. People with atrial fibrillation are five times more likely to suffer a stroke than the rest of the population. about one third of them will suffer a stroke in the future. The FA prevalence is increasing with the ageing of the population and affects 4% of the Spanish population over 40 years.
Rainer Krause, Chief delegate of Bayer, Spain, said: have the experience of Almirall in the cardiovascular area as the perfect partner to bring the benefits of Rivaroxaban to patients and physicians in Spain, which require a convenient and highly effective therapy against blood clots to prevent stroke and treat deep venous thrombosis. Almirall and Bayer will work together to make it possible to ”.
Enrique DomÃnguez, Director General of Almirall, Spain has added: Bayer’s Rivaroxaban fits perfectly in the cardiovascular portfolio of Almirall, where the company already has other therapeutic solutions established successfully in the market. “This agreement represents a step more in order to take new patients and prescribers Xarelto ®.”
about Rivaroxaban
Rivaroxaban is a new oral anticoagulant found in the laboratories of Bayer HealthCare Wuppertal in Germany. The drug has a rapid onset of action with a predictable dose-response, high bioavailability, does not need regular monitoring, and has low risk of interaction with other drugs and foods.
Rivaroxaban is marketed under the brand name Xarelto ® for the prevention of the disease venous thromboembolic (ETV) in adult patients after hip or knee replacement surgery. To date, Rivaroxaban is approved in more than 110 countries around the world.
Rivaroxaban is a new oral anticoagulant approved in three directions in Europe: prevention of stroke and systemic embolism in adult patients with atrial fibrillation (AF) non-valvular and one or more risk factors, treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) after an acute DVT in adults, and for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee surgery.
The extensive programme of clinical trials of Rivaroxaban makes it the oral inhibitor direct factor Xa most studied and widely published. In studies, reported and ongoing, participate more than 75,000 patients which evaluates the drug in the prevention and treatment of disorders of venous and arterial thromboembolic in a wide range of acute and chronic conditions, including the prevention of stroke in patients with atrial fibrillationthe treatment of DVT and prevention of recurrent DVT or EP, and secondary prevention of acute coronary syndrome.
Venous thromboembolism (VTE) is caused by the blockage of a blood vessel by a blood clot. In the EU there are approximately 550,000 deaths related to VTE each year and is estimated to be the third most common cardiovascular disease.
on atrial fibrillation
atrial fibrillation is the most common cardiac arrhythmia, and affects more than 6 million people in Europe. People with atrial fibrillation are five times more likely to suffer a stroke than the rest of the population. about one third of them will suffer a stroke in the future. In patients with atrial fibrillation, the irregular heart rate makes them more vulnerable to the formation of a thrombus in the Atria that can reach the brain and cause a stroke. Stroke causes damage in the brain and can lead to physical disability and altering the behavior of the individual who is suffering or even death.
on deep venous thrombosis (DVT)
La DVT is the formation of a blood clot in a deep vein, which partially or completely blocks the flow of blood. However, deep venous thrombosis can evolve and become an EP potentially fatal if the blood clot breaks and travels to the lungs and ultimately blocks a blood vessel in the body.
about Bayer HealthCare
Bayer HealthCare is a subsidiary of Bayer AG with headquarters in Leverkusen, their drugs and products for the medical sector, is among the main innovative companies in the health sector. The company brings together the divisions Animal Health, Consumer Care, Diabetes Care, Intendis and Bayer HealthCare Pharmaceuticals. The aim of Bayer HealthCare is the research, development, production and marketing of innovative products to improve the health of human beings and animals from around the world.
Bayer HealthCare adheres to the Spanish code of practice of Farmaindustria.
About Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health. With headquarters in Barcelona (Spain), Almirall researches, develops, produces and sells drugs own r & d and licensing with the aim of improving the health and well-being of people.
The therapeutic areas in which concentrates its resources in research are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), gastrointestinal disorders, psoriasis and other skin complaints forms.
Almirall drugs are now present in more than 70 countries. It has direct presence in Europe and Latin America through subsidiaries 12.
